Table 5.
Judgment regarding 1 mg uptitration at Week 4
| Dose in First Treatment Period, Subgroup (n) | Improved SL and TST at Week 4, n (%) | Not Eligible, n | Eligiblea, n |
|---|---|---|---|
|
Elderly | |||
| 1 mg, with psychiatric disorders (n = 34) |
29 (85.3) |
32 |
2 |
| 2 mg, with psychiatric disorders (n = 42) |
39 (92.9) |
41 |
1 |
| 1 mg, without psychiatric disorders (n = 40) |
34 (85.0) |
38 |
2 |
| 2 mg, without psychiatric disorders (n = 36) |
32 (88.9) |
35 |
1 |
| Total elderly (n = 152) |
134 (88.2) |
146 |
6 |
|
Nonelderly | |||
| 2 mg, with psychiatric disorders (n = 41) |
36 (87.8) |
39 |
2 |
| 3 mg, with psychiatric disorders (n = 35) |
28 (80.0) |
32 |
3 |
| 2 mg, without psychiatric disorders (n = 41) |
31 (75.6) |
36 |
5 |
| 3 mg, without psychiatric disorders (n = 38) |
33 (86.8) |
37 |
1 |
| Total nonelderly (n = 155) | 128 (82.6) | 144 | 11 |
a Patients in the elderly 2-mg group and the nonelderly 3-mg group for whom dose escalation would be appropriate were given a 1-mg placebo tablet.
SL = sleep latency; TST = total sleep time.